Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 1, 2014, Pages 26-32

  Sakairi, Yuichi ^a   Sato, Kenichi ^b   Itoga, Sakae ^b   Saegusa, Fumie ^b   Matsushita, Kazuyuki ^b   Nakajima, Takahiro ^a   Yoshida, Shigetoshi ^a   Takiguchi, Yuichi ^a   Nomura, Fumio ^b   Yoshino, Ichiro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biomarker; Bronchoscope; Bronchoscopic ultrasound; Microsampling

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; SODIUM CHLORIDE;

ARTICLE; BIOPSY NEEDLE; CANCER CELL; CANCER CYTODIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; FUSION GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPH NODE; MALE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; SAMPLING; TRANSBRONCHIAL ASPIRATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BRONCHI; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; ENDOSONOGRAPHY; FEMALE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; SOLUTIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891776543     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000024     Document Type: Article

References (21)

1. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388
2. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128
3. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12:1004-1012
4. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012;30(Suppl):abstr 7508
5. Suehara Y, Arcila ME, Dela Cruz Drilon AE, et al. KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial. J Clin Oncol 2012;30:(Suppl):abstr 7578
6. Novello S, Abrey LE, Grossi F, et al. Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases; a phase II trial. J Clin Oncol 2009;27(Suppl):abstr 8077
7. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-e24
8. Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007;132:597-602
9. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010;16:4938-4945
10. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue; personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010;16:4909-4911
11. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295
12. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142
13. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009;11:140-147
14. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription- PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624
15. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381
16. Goyal S, Mohan H, Uma H, et al. Rinse fluid and imprint smear cytology of bronchial biopsies in diagnosis of lung tumors. Diagn Cytopathol 2012;40:98-103
17. Soda M, Isobe K, Inoue A, et al.; North-East Japan Study Group; ALK Lung Cancer Study Group. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 2012;18:5682-5689
18. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-7282
19. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006;97:642-648
20. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin Cancer Res 2007;13:4954-4955
21. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009;4:809-815